Clinical Utility of Circulating Tumor Cells

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.

The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.

The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.

Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.

The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.

China's NMPA accepted a supplemental application expanding toripalimab's perioperative NSCLC indication to stage II-III disease.

An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.